Indian New Treatment for Asthma & COPD Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast periodIn India, the Asthma is one of most common chronic disease. In India about 6% of children and 2% of adults have asthma. Nearly 7 million of sufferers are men and just over six million women, while the worst-affected age group is the 15-35-year-olds. The prevalence of occurrence of Asthma in India amongst the Indian children has increased exponentially due to growing air pollution and poor quality of air. It is estimated that in every 1.5-2 crore asthma patients, at least one in every 10 asthma patient globally lives in India. India contributes very significantly to mortality from COPD 102.3/100,000 and 6,740,000 DALYs out of world total of 27,756,000 DALYs; thus significantly affecting health related Quality of Life in the country. About XX% of people in India have COPD who were smokers or former smokers. There are 30 million COPD patients in India. India contributes a significant and growing percentage of COPD mortality which is estimated to be amongst the highest in the world i.e. more than 64.7 estimated age standardized death rate per 100,000 amongst both sexes. This would translate to about 556,000 in case of India (>20%) out of a world total of 2,748,000 annually. COPD is the second most common cause of NCD-related deaths in India, with the age-specific prevalence of COPD increasing rapidly after the age of 30 years. The risk factors for the development of Asthma are a complex interplay of genetic susceptibility and exposure to environmental particulate allergens and substances like indoor and outdoor allergens, tobacco smoke, chemical irritants in the workplace and air pollution.
The increasing prevalence of asthma, increase in world ageing population, technological advancement in the treatment of asthma, increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness are the major factors that drive the growth of the Asthma. The other drivers can be considered as the increasing need for better clinical and therapeutics for asthma in the light of the covid-19 pandemic. An increasing number of product launches are expected to drive the growth of the asthma and COPD drugs market. An increase in the awareness programmes and initiatives to support the major pharmaceutical players to implement advanced R&D and drug development will boost this market in India.